Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

CCSVI is associated with multiple sclerosis.
[American Academy of Neurology, Washington, 18-25 April 2015].
Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes.
Resveratrol effects on astrocyte function: Relevance to neurodegenerative diseases.
Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes.
Placebo power.
Fingolimod (Gilenya) licence extended
Role of the innate and adaptive immune responses in the course of multiple sclerosis.
Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique.
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
A comparative study of CSF neurofilament light and heavy chain protein in MS.
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Multiple sclerosis: Five new things.
NMO spectrum presenting as partial myelitis.
SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
Exploring brainstem function in multiple sclerosis by combining brainstem reflexes, evoked potentials, clinical and MRI investigations.
Coping strategies and mood profiles in patients with multiple sclerosis.
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
White matter atrophy and cognitive dysfunctions in neuromyelitis optica.
Accelerometer output and its association with energy expenditure in persons with multiple sclerosis.
Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis.
A palliative care hotline for multiple sclerosis: A pilot feasibility study.
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.
Evidence that nuclear factor IA inhibits repair after white matter injury.

Pages